Antioxidant Vitamins and Zinc Therapy for Intermediate Risk of Advanced Age-Related Macular Degeneration

The Age-Related Eye Disease Study (AREDS) and its follow-up are research efforts focused on understanding the progression of age-related macular degeneration (AMD) and cataracts. AMD is a condition that affects the central part of the retina, leading to vision loss, while cataracts cause clouding of the eye's lens. This study initially aimed to identify potential risk factors associated with AMD and cataracts, with a special focus on nutritional factors. The results indicated that a combination of antioxidant vitamins and zinc could reduce the risk of developing advanced AMD and associated vision loss, especially in those with an intermediate risk. Following the completion of the initial trial, participants were invited for an additional five-year follow-up to gather more data on the natural course of AMD and cataracts. In the AREDS2 phase, the study evolved into a multi-center trial evaluating the effects of oral supplementation with high doses of lutein, zeaxanthin, and omega-3 fatty acids as treatments for AMD, cataracts, and moderate vision loss. Participants undergo regular ocular examinations, and the study records historical data at each visit. The primary outcomes of interest are changes in visual acuity and photographic documentation of the two diseases. The study also aims to monitor any adverse effects associated with the AREDS treatment. Participants who complete AREDS2 are invited for annual follow-ups for at least five years to collect additional data.